Longitudinal Whole-Exome Sequencing Revealed Early Clonal Suppression and Delayed Resistance Evolution in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Ibrutinib
This project contains longitudinal whole-exome sequencing data from a multicenter Korean cohort of patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib. Whole-exome sequencing was performed on pretreatment samples, paired samples obtained approximately 6 months after treatment initiation, and additional progression or extended follow-up samples in a subset of patients. The study was designed to characterize longitudinal genomic changes during ibrutinib therapy and to examine variant dynamics across treatment timepoints.